Zoe June Assaf on Muck Rack

Zoe June Assaf

As seen in: Nature, Cell Press, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zoe June

Contact Zoe June, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial | Nature Medicine

|
By Elizabeth A. Mittendorf, Zoe June Assaf, Nadia Harbeck, Kyung Hae Jung, Joohyuk Sohn, Melinda L. Telli, Max Dieterich
| Nature Verified
Abstract Previously published results demonstrated that the randomized phase 3 IMpassion031 trial met its primary objective: adding atezolizumab to neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rate in patients with stage II/III triple-negative breast cancer (TNBC). Here we report the prespecified final analysis of the secondary endpoints with 3 years’ follow-up, together with exploratory analyses of circulating tumor (ct)DNA.
Open in Who Shared Issue with article?

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

|
By Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel, Xiangnan Guan, Hartmut Koeppen, Zoe June Assaf, Barzin Y. Nabet, Adrian Waddell, Kobe Yuen, Sophia Maund, Ethan S Sokol, Jennifer M. Giltnane, Amber Schedlbauer, Eloisa Fuentes, James Cowan, Edward E. Kadel, Viraj Degaonkar, Alexander Y. Andreev-Drakhlin, Patrick Williams, Corey Carter, Suyasha Gupta, Elizabeth E. Steinberg, Yohann Loriot, Joaquim Bellmunt, Petros Grivas, Jonathan Rosenberg, Matthew D. Galsky, Thomas Powles, Sanjeev Mariathasan, Romain Banchereau
| Cell Press Verified
Keywords urothelial carcinoma transcriptomics molecular heterogeneity PD-L1 blockade patient stratification digital pathology Get full text access Log in, subscribe or purchase for full access. References 1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 1992; 11:3887-3895 2. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...
Open in Who Shared Issue with article?

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial - Nature Medicine

|
By Solange Peters, Tony S Mok, Ernest Nadal, Shunichi Sugawara, Chong-Jen Yu, Sarah M. Shagan, Zoe June Assaf
| Nature Verified
Abstract Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients.
Open in Who Shared Issue with article?
See all 6 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified